Cyclerion Therapeutics, Inc.
CYCN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.09 | 0.00 | -0.02 |
| FCF Yield | -3.56% | -5.63% | -15.15% | 4.39% |
| EV / EBITDA | -2.92 | -3.55 | -1.89 | 9.89 |
| Quality | ||||
| ROIC | -10.55% | -19.51% | -16.59% | 5.67% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.27 | 1.55 | 0.68 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,418,528.58% | 1,295,347.59% | 89.46% | 25.29% |
| Free Cash Flow Growth | 47.51% | 48.04% | -368.89% | 120.98% |
| Safety | ||||
| Net Debt / EBITDA | 4.68 | 1.80 | 2.50 | -6.44 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 10.29 | 508.06 | 645.56 | 27.71 |